XML 11 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenues [Abstract]    
Revenue $ 52,443 $ 41,873
Operating expenses    
Cost of revenue 16,979 18,051
Research and development 24,203 30,245
Sales and marketing 23,047 22,319
General and administrative 17,399 19,597
Amortization of intangible assets 419 423
Total operating expenses 82,047 90,635
Loss from operations (29,604) (48,762)
Interest and other income, net 2,679 4,222
Interest expense [1] (2,905) (2,993)
Net loss (29,830) (47,533)
Add: Net (income) loss attributable to noncontrolling interest (22) 26
Net loss attributable to Adaptive Biotechnologies Corporation $ (29,852) $ (47,507)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic $ (0.2) $ (0.33)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic 149,195,028 145,787,527
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted $ (0.2) $ (0.33)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted 149,195,028 145,787,527
[1] Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 8, Revenue Interest Purchase Agreement for details on the Purchase Agreement.